GlassScriptPhysician profile
Leslie Diane Kovar
NPI 1316719511
$1,422.09
in general payments reported to CMS, 2019-2025
16 companies · $97.86 in 2025
The $97.86 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,324 · 2025: $97.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.98 | 2024 | Lokelma |
| Vifor Pharma, INC. | $205.67 | 2024 | Veltassa |
| Ardelyx, INC. | $195.52 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $164.24 | 2024 | |
| Travere Therapeutics, INC. | $153.61 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $106.43 | 2024 | Jynarque |
| Fresenius USA Marketing, INC. | $78.43 | 2024-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $65.59 | 2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $45.60 | 2024 | Rayaldee |
| Amgen INC. | $32.89 | 2024 | Tavneos |
| Akebia Therapeutics INC | $25.61 | 2025 | Vafseo |
| Novo Nordisk INC | $22.01 | 2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $21.83 | 2024 | |
| Daiichi Sankyo INC. | $19.02 | 2024 | Injectafer |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.18 | 2024 | Jynarque |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $14.48 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Kovar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.